ICD-10 Codes for Hormone Receptor-Positive Breast Cancer
For hormone receptor-positive breast cancer, use the primary malignant neoplasm codes with laterality specification: C50.x11 for right breast and C50.x12 for left breast, where 'x' represents the specific anatomical subsite (0-9).
Code Structure and Laterality
The ICD-10-CM coding system for breast cancer follows a hierarchical structure with mandatory 7th character extensions for laterality 1:
- Right breast: Always ends in 1 (e.g., C50.911 for right breast, unspecified site)
- Left breast: Always ends in 2 (e.g., C50.912 for left breast, unspecified site)
- Bilateral: Would use 3 if applicable, though bilateral codes require separate coding for each side when no specific bilateral code exists 1
Specific Anatomical Site Codes
The complete code requires specifying the anatomical location within the breast (C50.x):
- C50.0: Nipple and areola
- C50.1: Central portion of breast
- C50.2: Upper-inner quadrant
- C50.3: Lower-inner quadrant
- C50.4: Upper-outer quadrant
- C50.5: Lower-outer quadrant
- C50.6: Axillary tail
- C50.8: Overlapping sites
- C50.9: Breast, unspecified
Important Coding Considerations
The ICD-10 code itself does not specify hormone receptor status 2. The hormone receptor-positive designation is documented separately in the pathology report through immunohistochemistry (IHC) evaluation of ER and PR status 3. Tumors with 1-100% ER staining are considered ER-positive and eligible for endocrine therapy 2.
Common Pitfalls
- Do not use placeholder X unless the code requires fewer than 6 characters before the 7th character laterality designation 1
- Always verify the specific anatomical subsite rather than defaulting to "unspecified" when location is documented
- Code each side separately for bilateral disease using the appropriate laterality digit for each tumor 1
- Remember that ICD-10 codes identify the anatomical diagnosis only—receptor status, HER2 status, and tumor grade are documented through pathology reporting systems, not ICD-10 codes 3, 2
Clinical Context
While the ICD-10 code captures the anatomical diagnosis, treatment decisions for HR-positive breast cancer depend on the documented receptor status from pathology 4. Postmenopausal women with HR-positive disease receive aromatase inhibitors as preferred first-line endocrine therapy 4, while premenopausal women require ovarian suppression or ablation combined with endocrine therapy 4.